Home › Open-Angle Glaucoma › NCT06848946

Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone

Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intracameral Implant) in Conjunction With Cataract Surgery vs. Cataract Surgery Alone

Who can join

Ages 45 and older · All sexes

Inclusion Criteria:

* Cataract diagnosis: clinically significant age-related cataract eligible for phacoemulsification in the study eye.
* OAG or OHT diagnosis: either OAG (i.e. primary, pseudoexfoliation, or pigmentary glaucoma) or OHT in the study eye (i.e., eye to undergo cataract surgery)

Exclusion Criteria:

* Active corneal inflammation or edema.
* Retinal disorders not associated with glaucoma.

About the study

This trial will evaluate the safety and IOP -lowering efficacy of administering an iDose TR (travoprost intracameral implant) in conjunction with cataract surgery compared to cataract surgery alone

What is being tested

• iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery (combination product)
• Sham procedure in conjunction with cataract surgery (procedure)

Sponsor: Glaukos Corporation · Participants: 132 · Started: Jan 13, 2025

Contact the study team

• Study Manager · Phone: 949-739-8749

Official record on ClinicalTrials.gov — NCT06848946

Locations in the U.S.

Conditions

• Open-Angle Glaucoma
• Ocular Hypertension

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.